GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Veterinary Surgery, Wiley, Vol. 49, No. 6 ( 2020-08), p. 1132-1143
    Abstract: To report the outcomes of dogs with lesions of the genitourinary tract treated by vaginectomy or vulvovaginectomy. Study design Multi‐institutional retrospective study. Animals Female dogs that underwent vulvovaginectomy, complete vaginectomy, or subtotal vaginectomy from 2003 to 2018 with complete medical records and a minimum of 60 days follow‐up. Methods Data collected from medical records included preoperative, intraoperative, and postoperative data, such as the occurrence of urinary incontinence (UIC), disease recurrence, and death/euthanasia. Results This study included 21 dogs. Four dogs had vulvovaginectomy, six had complete vaginectomy, and 11 had a subtotal vaginectomy performed. The mean age at surgery was 9.2 years (SD, 3.3). Thirteen dogs were intact at presentation. Smooth muscle tumors were diagnosed most commonly (10 leiomyomata, three leiomyosarcomas, two leiomyofibromas). The median duration of follow‐up was 520 days (range, 71‐1955). Major complications requiring revision surgery were recorded in two dogs. Postoperative UIC occurred in six of 21 dogs, resolving spontaneously within 60 days in three dogs. Dogs with malignant tumors (n = 6) survived at least 71 days (median, 626; 95% CI, 71‐1245), and recurrence of disease occurred in two dogs. In dogs with benign tumors (n = 15), the median survival time was not reached. These dogs survived at least 104 days and had no recurrence of the disease. Conclusion Vaginectomy and vulvovaginectomy resulted in prolonged survival and low rates of major complications and UIC. Clinical significance This study provides evidence to recommend that the risks of this procedure and expectations should be discussed with clients.
    Type of Medium: Online Resource
    ISSN: 0161-3499 , 1532-950X
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 1491071-8
    SSG: 22
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Veterinary and Comparative Oncology, Wiley, Vol. 20, No. 2 ( 2022-06), p. 484-490
    Abstract: Sertoli cell tumours are one of the most common canine testicular neoplasia. These tumours are significantly more likely to arise in cryptorchid dogs and are often functional, oestrogen‐secreting tumours which can lead to fatal myelotoxicity. The goal of this study was to describe the outcome of dogs with oestrogen‐induced bone marrow suppression secondary to Sertoli cell tumours in seven client‐owned dogs. Medical records from April 1, 2011 through April 1, 2021 were reviewed to identify dogs that underwent surgical management of a Sertoli cell tumour with documented bone marrow suppression. Overall, 5/7 dogs required transfusion of blood products peri‐operatively. Cases 1 and 6 received a transfusion of packed red blood cells (RBC) prior to surgery and case 5 required a transfusion of whole blood. Case 1 also required a transfusion of platelets before surgery. Post‐operatively, cases 1 and 2 received packed RBC's and case 6 received two transfusions of whole blood. Case 3 required transfusions of both fresh frozen plasma and platelets post‐operatively. All dogs survived to discharge and 6/7 dogs had documented improvement in haematopoietic values. Two dogs remained chronically thrombocytopenic. The median hospital stay was 4 days. One dog died within 4 weeks of surgery from worsening pancytopenia. Survival for greater than 1 year was documented in 4/7 dogs, and one dog was lost to follow‐up 4 months post‐operatively. One dog remained severely pancytopenic 4 weeks post‐operatively and received oral lithium treatment. Improvements in all blood cell lines were observed within the 4 weeks and resolution of pancytopenia within 6 weeks. Historically, the prognosis for dogs with bone marrow suppression secondary to Sertoli cell tumours was guarded to poor. This report documented improved outcomes for dogs that underwent surgery, including one dog that received lithium chloride as treatment for Sertoli cell tumour‐induced bone marrow suppression.
    Type of Medium: Online Resource
    ISSN: 1476-5810 , 1476-5829
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2129634-0
    SSG: 22
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Wiley ; 2021
    In:  Veterinary and Comparative Oncology Vol. 19, No. 4 ( 2021-12), p. 603-603
    In: Veterinary and Comparative Oncology, Wiley, Vol. 19, No. 4 ( 2021-12), p. 603-603
    Type of Medium: Online Resource
    ISSN: 1476-5810 , 1476-5829
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2129634-0
    SSG: 22
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Veterinary and Comparative Oncology, Wiley, Vol. 18, No. 4 ( 2020-12), p. 699-705
    Abstract: Feline sarcoids (or cutaneous fibropapillomas) are rare dermal neoplasms. There are currently no reported statistics concerning their clinical behaviour. Our objective with this retrospective, multi‐institutional study was to describe the clinical presentation and biological behaviour of sarcoids in cats and to determine the oncologic outcome following surgical resection. Medical records from a laboratory database and six contributing institutions were searched to identify cats with histologically confirmed sarcoids. Forty‐two cats were included in the study. The majority of sarcoids occurred on the face, particularly rostral locations such as the lips and nasal planum. Complete and incomplete histologic excision was achieved in 18 and 21 cats, respectively. The overall local recurrence rate was 40.5%. Complete histologic excision was associated with a significantly lower local recurrence rate (11.1%) and longer disease‐free interval (not reached) compared with cats with incompletely excised sarcoids (66.7% and 250 days, respectively). The 1‐ and 2‐year local recurrence rates were 0% and 7%, respectively, for cats with complete histologic excision, and 67% at both time intervals for cats with incomplete histologic excision. Five of the cats (83.3%) treated with curative‐intent surgical revision following local tumour recurrence had no further local recurrence. All cats that died secondary to tumour‐related causes had initial incomplete histologic excision and were euthanized because of local recurrence. Wide surgical resection of feline sarcoids is recommended to achieve complete histologic excision, local tumour control and a potential cure. For cats with incomplete histologic excision or local tumour recurrence, repeat surgical resection is recommended.
    Type of Medium: Online Resource
    ISSN: 1476-5810 , 1476-5829
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2129634-0
    SSG: 22
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Journal of Veterinary Internal Medicine, Wiley, Vol. 35, No. 6 ( 2021-11), p. 2722-2729
    Abstract: Limited information currently exists regarding the clinical progression and outcomes of cats that undergo choledochal stenting as a treatment for extrahepatic biliary obstruction (EHBO). Hypothesis/Objectives Describe clinical characteristics, indications for choledochal stent placement, procedure, and outcomes in a cohort of cats undergoing choledochal stenting and evaluate risk factors associated with survival as well as recurrence of EHBO in affected cats. Animals Twenty‐three client‐owned cats undergoing choledochal stent placement. Methods Retrospective study. Medical records from 6 academic institutions were reviewed, and data were extracted and analyzed statistically. Results Median age of cats was 10.1 years (range, 2‐16), and all cats had at least 2 clinical signs. Most common clinical signs were vomiting in 20/22 (90.9%), inappetence in 19/22 (86.4%), and lethargy in 19/23 (82.6%). Procedural complications were uncommon and rarely related to the stenting procedure. Clinical signs improved postoperatively in 15/20 (75.0%) cats and serum total bilirubin concentration decreased postoperatively in 13/19 (68.4%) cats. Eighteen (78.3%) cats survived to discharge. Recurrence of EHBO was documented in 7/18 (38.9%) cats that survived to discharge. Cholelithiasis was associated with recurrence of EHBO. Median survival time for cats that survived to discharge was 931 days (range, 19‐3034). Absence of peritoneal effusion was associated with survival to discharge. Conclusions and Clinical Importance Choledochal stenting was an effective treatment modality in cats with EHBO with few procedural complications and potential for prolonged survival, but substantial risk for recurrence of EHBO was identified.
    Type of Medium: Online Resource
    ISSN: 0891-6640 , 1939-1676
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2177690-8
    SSG: 22
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Journal of Veterinary Internal Medicine, Wiley, Vol. 34, No. 1 ( 2020-01), p. 274-282
    Abstract: Lower urinary tract transitional cell carcinoma (TCC) is an important but rarely described disease of cats. Objectives To report the clinical characteristics, treatments, and outcomes in a cohort of cats with lower urinary tract TCC and to test identified variables for prognostic relevance. Animals One‐hundred eighteen client‐owned cats with lower urinary tract carcinoma. Methods Medical records were retrospectively reviewed to obtain information regarding clinical characteristics, treatments, and outcomes. Recorded variables were analyzed statistically. Results Median age of affected cats was 15 years (range, 5.0‐20.8 years) and median duration of clinical signs was 30 days (range, 0‐730 days). The trigone was the most common tumor location (32/118; 27.1%) as assessed by ultrasound examination, cystoscopy, or both. Treatment was carried out in 73 of 118 (61.9%) cats. Metastatic disease was documented in 25 of 118 (21.2%) cats. Median progression‐free survival and survival time for all cats were 113 days (95% confidence interval [CI], 69‐153) and 155 days (95% CI, 110‐222), respectively. Survival increased significantly ( P 〈  .001) when comparing cats across the ordered treatment groups: no treatment, treatment without partial cystectomy, and treatment with partial cystectomy. Partial cystectomy (hazard ratio [HR], 0.31; 95% CI, 0.17‐0.87) and treatment with nonsteroidal anti‐inflammatory drugs (HR, 0.55; 95% CI, 0.33‐0.93) were significantly associated with longer survival times. Conclusions and Clinical Importance The results support treatment using partial cystectomy and NSAIDs in cats with TCC.
    Type of Medium: Online Resource
    ISSN: 0891-6640 , 1939-1676
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2177690-8
    SSG: 22
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...